Home Newsfeeds Mizuho Maintains Buy on Entegris, Lowers Price Target to $146

Mizuho Maintains Buy on Entegris, Lowers Price Target to $146

Mizuho analyst Kieran De Brun maintains Entegris (NASDAQ:ENTG) with a Buy and lowers the price target from $160 to $146.

byBenzinga Newsdesk

July 7, 2022

1 minute read

Mizuho analyst Kieran De Brun maintains Entegris (NASDAQ:ENTG) with a Buy and lowers the price target from $160 to $146.

Analyst Ratings

Where Cognex Stands With Analysts

By Benzinga Insights

August 1, 1:05 PM

Within the last quarter, Cognex (NASDAQ:CGNX) has observed the following analyst ratings:

CGNX

S&P 500, Nasdaq Futures Point To Lackluster Start As Friday’s Jobs Report, Pre-Holiday Mood Keeps Sentiment Subdued

By Shanthi Rexaline

September 2, 7:16 AM

The major U.S. index futures point to a nervous start on Friday, as investors choose to exercise restraint ahead of the non-farm payrolls report for August.

AVGO

Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M In Sales During 2024

By Happy Mohamed

May 30, 9:04 AM

VELDONA® Pet will hit shelves in Taiwan in June, with launches in other regions to follow Multiple new VELDONA® Pet products set to launch as Ainos enters the growing global pet care market SAN DIEGO, CA /

AIMD

Why Fear Level Among US Investors Is Decreasing

By Lisa Levin

August 1, 4:11 AM

The CNN Money Fear and Greed index showed that the overall fear level continued to ease further in the US equity markets, following another surge in the Dow Jones on Friday. U.S. stocks settled higher on Friday after the Federal Reserve, last week, increased interest rates by 75 bps in a bid to combat the surging inflation level.

AAPL

Mizuho Maintains Buy on Entegris, Lowers Price Target to $146

Related Posts

Where Cognex Stands With Analysts

S&P 500, Nasdaq Futures Point To Lackluster Start As Friday’s Jobs Report, Pre-Holiday Mood Keeps Sentiment Subdued

Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M In Sales During 2024

Why Fear Level Among US Investors Is Decreasing